Cargando…

Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model

BACKGROUND: Cervical cancer (CC) and genital warts (GW) are a significant public health issue in Venezuela. Our objective was to assess the cost-effectiveness of the two available vaccines, bivalent and quadrivalent, against Human Papillomavirus (HPV) in Venezuelan girls in order to inform decision-...

Descripción completa

Detalles Bibliográficos
Autores principales: Bardach, Ariel Esteban, Garay, Osvaldo Ulises, Calderón, María, Pichón-Riviére, Andrés, Augustovski, Federico, Martí, Sebastián García, Cortiñas, Paula, Gonzalez, Marino, Naranjo, Laura T., Gomez, Jorge Alberto, Caporale, Joaquín Enzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289055/
https://www.ncbi.nlm.nih.gov/pubmed/28148228
http://dx.doi.org/10.1186/s12889-017-4064-7
_version_ 1782504447189975040
author Bardach, Ariel Esteban
Garay, Osvaldo Ulises
Calderón, María
Pichón-Riviére, Andrés
Augustovski, Federico
Martí, Sebastián García
Cortiñas, Paula
Gonzalez, Marino
Naranjo, Laura T.
Gomez, Jorge Alberto
Caporale, Joaquín Enzo
author_facet Bardach, Ariel Esteban
Garay, Osvaldo Ulises
Calderón, María
Pichón-Riviére, Andrés
Augustovski, Federico
Martí, Sebastián García
Cortiñas, Paula
Gonzalez, Marino
Naranjo, Laura T.
Gomez, Jorge Alberto
Caporale, Joaquín Enzo
author_sort Bardach, Ariel Esteban
collection PubMed
description BACKGROUND: Cervical cancer (CC) and genital warts (GW) are a significant public health issue in Venezuela. Our objective was to assess the cost-effectiveness of the two available vaccines, bivalent and quadrivalent, against Human Papillomavirus (HPV) in Venezuelan girls in order to inform decision-makers. METHODS: A previously published Markov cohort model, informed by the best available evidence, was adapted to the Venezuelan context to evaluate the effects of vaccination on health and healthcare costs from the perspective of the healthcare payer in an 11-year-old girls cohort of 264,489. Costs and quality-adjusted life years (QALYs) were discounted at 5%. Eight scenarios were analyzed to depict the cost-effectiveness under alternative vaccine prices, exchange rates and dosing schemes. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: Compared to screening only, the bivalent and quadrivalent vaccines were cost-saving in all scenarios, avoiding 2,310 and 2,143 deaths, 4,781 and 4,431 CCs up to 18,459 GW for the quadrivalent vaccine and gaining 4,486 and 4,395 discounted QALYs respectively. For both vaccines, the main determinants of variations in the incremental costs-effectiveness ratio after running deterministic and probabilistic sensitivity analyses were transition probabilities, vaccine and cancer-treatment costs and HPV 16 and 18 distribution in CC cases. When comparing vaccines, none of them was consistently more cost-effective than the other. In sensitivity analyses, for these comparisons, the main determinants were GW incidence, the level of cross-protection and, for some scenarios, vaccines costs. CONCLUSIONS: Immunization with the bivalent or quadrivalent HPV vaccines showed to be cost-saving or cost-effective in Venezuela, falling below the threshold of one Gross Domestic Product (GDP) per capita (104,404 VEF) per QALY gained. Deterministic and probabilistic sensitivity analyses confirmed the robustness of these results. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12889-017-4064-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5289055
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52890552017-02-09 Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model Bardach, Ariel Esteban Garay, Osvaldo Ulises Calderón, María Pichón-Riviére, Andrés Augustovski, Federico Martí, Sebastián García Cortiñas, Paula Gonzalez, Marino Naranjo, Laura T. Gomez, Jorge Alberto Caporale, Joaquín Enzo BMC Public Health Research Article BACKGROUND: Cervical cancer (CC) and genital warts (GW) are a significant public health issue in Venezuela. Our objective was to assess the cost-effectiveness of the two available vaccines, bivalent and quadrivalent, against Human Papillomavirus (HPV) in Venezuelan girls in order to inform decision-makers. METHODS: A previously published Markov cohort model, informed by the best available evidence, was adapted to the Venezuelan context to evaluate the effects of vaccination on health and healthcare costs from the perspective of the healthcare payer in an 11-year-old girls cohort of 264,489. Costs and quality-adjusted life years (QALYs) were discounted at 5%. Eight scenarios were analyzed to depict the cost-effectiveness under alternative vaccine prices, exchange rates and dosing schemes. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: Compared to screening only, the bivalent and quadrivalent vaccines were cost-saving in all scenarios, avoiding 2,310 and 2,143 deaths, 4,781 and 4,431 CCs up to 18,459 GW for the quadrivalent vaccine and gaining 4,486 and 4,395 discounted QALYs respectively. For both vaccines, the main determinants of variations in the incremental costs-effectiveness ratio after running deterministic and probabilistic sensitivity analyses were transition probabilities, vaccine and cancer-treatment costs and HPV 16 and 18 distribution in CC cases. When comparing vaccines, none of them was consistently more cost-effective than the other. In sensitivity analyses, for these comparisons, the main determinants were GW incidence, the level of cross-protection and, for some scenarios, vaccines costs. CONCLUSIONS: Immunization with the bivalent or quadrivalent HPV vaccines showed to be cost-saving or cost-effective in Venezuela, falling below the threshold of one Gross Domestic Product (GDP) per capita (104,404 VEF) per QALY gained. Deterministic and probabilistic sensitivity analyses confirmed the robustness of these results. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12889-017-4064-7) contains supplementary material, which is available to authorized users. BioMed Central 2017-02-02 /pmc/articles/PMC5289055/ /pubmed/28148228 http://dx.doi.org/10.1186/s12889-017-4064-7 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Bardach, Ariel Esteban
Garay, Osvaldo Ulises
Calderón, María
Pichón-Riviére, Andrés
Augustovski, Federico
Martí, Sebastián García
Cortiñas, Paula
Gonzalez, Marino
Naranjo, Laura T.
Gomez, Jorge Alberto
Caporale, Joaquín Enzo
Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model
title Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model
title_full Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model
title_fullStr Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model
title_full_unstemmed Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model
title_short Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model
title_sort health economic evaluation of human papillomavirus vaccines in women from venezuela by a lifetime markov cohort model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289055/
https://www.ncbi.nlm.nih.gov/pubmed/28148228
http://dx.doi.org/10.1186/s12889-017-4064-7
work_keys_str_mv AT bardacharielesteban healtheconomicevaluationofhumanpapillomavirusvaccinesinwomenfromvenezuelabyalifetimemarkovcohortmodel
AT garayosvaldoulises healtheconomicevaluationofhumanpapillomavirusvaccinesinwomenfromvenezuelabyalifetimemarkovcohortmodel
AT calderonmaria healtheconomicevaluationofhumanpapillomavirusvaccinesinwomenfromvenezuelabyalifetimemarkovcohortmodel
AT pichonriviereandres healtheconomicevaluationofhumanpapillomavirusvaccinesinwomenfromvenezuelabyalifetimemarkovcohortmodel
AT augustovskifederico healtheconomicevaluationofhumanpapillomavirusvaccinesinwomenfromvenezuelabyalifetimemarkovcohortmodel
AT martisebastiangarcia healtheconomicevaluationofhumanpapillomavirusvaccinesinwomenfromvenezuelabyalifetimemarkovcohortmodel
AT cortinaspaula healtheconomicevaluationofhumanpapillomavirusvaccinesinwomenfromvenezuelabyalifetimemarkovcohortmodel
AT gonzalezmarino healtheconomicevaluationofhumanpapillomavirusvaccinesinwomenfromvenezuelabyalifetimemarkovcohortmodel
AT naranjolaurat healtheconomicevaluationofhumanpapillomavirusvaccinesinwomenfromvenezuelabyalifetimemarkovcohortmodel
AT gomezjorgealberto healtheconomicevaluationofhumanpapillomavirusvaccinesinwomenfromvenezuelabyalifetimemarkovcohortmodel
AT caporalejoaquinenzo healtheconomicevaluationofhumanpapillomavirusvaccinesinwomenfromvenezuelabyalifetimemarkovcohortmodel